Literature DB >> 28597452

Impact of the Triglyceride/High-Density Lipoprotein Cholesterol Ratio and the Hypertriglyceremic-Waist Phenotype to Predict the Metabolic Syndrome and Insulin Resistance.

Helene von Bibra1, Sarama Saha2, Alexander Hapfelmeier3, Gabriele Müller4, Peter E H Schwarz2,5,6.   

Abstract

Insulin resistance is the underlying mechanism for the metabolic syndrome and associated dyslipidaemia that theoretically implies a practical tool for identifying individuals at risk for cardiovascular disease and type-2-diabetes. Another screening tool is the hypertriglyceremic-waist phenotype (HTW). There is important impact of the ethnic background but a lack of studied European populations for the association of the triglyceride/high-density lipoprotein cholesterol (HDL-C) ratio and insulin resistance. This observational, retrospective study evaluated lipid ratios and the HTW for predicting the metabolic syndrome/insulin resistance in 1932 non-diabetic individuals from Germany in the fasting state and during a glucose tolerance test. The relations of triglyceride/HDL-C, total-cholesterol/HDL-C, and low-density lipoprotein cholesterol/HDL-C with 5 surrogate estimates of insulin resistance/sensitivity and metabolic syndrome were analysed by linear regression analysis and receiver operating characteristics (ROC) in participants with normal (n=1 333) or impaired fasting glucose (n=599), also for the impact of gender. Within the lipid ratios, triglyceride/HDL-C had the strongest associations with insulin resistance/sensitivity markers. In the prediction of metabolic syndrome, diagnostic accuracy was good for triglyceride/HDL-C (area under the ROC curve 0.817) with optimal cut-off points (in mg/dl units) of 2.8 for men (80% sensitivity, 71% specificity) and 1.9 for women (80% sensitivity, 75% specificity) and fair for HTW and HOMA-IR (area under the curve 0.773 and 0.761). These data suggest the triglyceride/HDL-C ratio as a physiologically relevant and practical index for predicting the concomitant presence of metabolic syndrome, insulin resistance and dyslipidaemia for therapeutic and preventive care in apparently healthy European populations. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28597452     DOI: 10.1055/s-0043-107782

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  15 in total

1.  Hypertriglyceridemic waist phenotype and abnormal glucose metabolism: a system review and meta-analysis.

Authors:  Chun-Ming Ma; Xiao-Li Liu; Na Lu; Rui Wang; Qiang Lu; Fu-Zai Yin
Journal:  Endocrine       Date:  2019-05-07       Impact factor: 3.633

2.  Impact of Lurasidone on Metabolic Parameters and Prolactin Levels Based on Differences of Psychiatric Diagnosis, Dosage, and Introducing Methods: An Observational Study.

Authors:  Masaru Nakamura; Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2022 Apr-Jun

3.  The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder States: A Retrospective Study in Chinese Population.

Authors:  Fei Guo; Zhentao Gong; Taniya Fernando; Lingshan Zhang; Xiaoyong Zhu; Yingli Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-04       Impact factor: 6.055

4.  Screening for Metabolic Syndrome Using an Integrated Continuous Index Consisting of Waist Circumference and Triglyceride: A Preliminary Cross-sectional Study.

Authors:  Peng Ju Liu; Hui Ping Lou; Yan Ning Zhu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-18       Impact factor: 3.168

5.  Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology.

Authors:  Bahira Shahim; Viveca Gyberg; Dirk De Bacquer; Kornelia Kotseva; Guy De Backer; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén
Journal:  Cardiovasc Diabetol       Date:  2018-01-24       Impact factor: 9.951

6.  Triglycerides/Glucose and Triglyceride/High-Density Lipoprotein Cholesterol Indices in Normal and Preeclamptic Pregnancies: A Longitudinal Study.

Authors:  Natalia Elvira Poveda; María Fernanda Garcés; Aquiles Enrique Darghan; Silvia Alejandra Blanco Jaimes; Estefania Pulido Sánchez; Luz Amparo Díaz-Cruz; Carmen Doris Garzón-Olivares; Mario Orlando Parra-Pineda; Alejandro Antonio Bautista-Charry; Edith Ángel Müller; Héctor Fabio Sandoval Alzate; Luis Miguel Maldonado Acosta; Elizabeth Sanchez; Ariel Iván Ruíz-Parra; Jorge Eduardo Caminos
Journal:  Int J Endocrinol       Date:  2018-08-06       Impact factor: 3.257

Review 7.  Association between insulin resistance and the development of cardiovascular disease.

Authors:  Valeska Ormazabal; Soumyalekshmi Nair; Omar Elfeky; Claudio Aguayo; Carlos Salomon; Felipe A Zuñiga
Journal:  Cardiovasc Diabetol       Date:  2018-08-31       Impact factor: 9.951

8.  Anthropometrics, Metabolic Syndrome, and Mortality Hazard.

Authors:  Nir Y Krakauer; Jesse C Krakauer
Journal:  J Obes       Date:  2018-07-12

9.  Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the DIASTOLIC study).

Authors:  Gaurav Singh Gulsin; Emer M Brady; Daniel J Swarbrick; Lavanya Athithan; Joseph Henson; Emma Baldry; John McAdam; Anna-Marie Marsh; Kelly S Parke; Joanne V Wormleighton; Eylem Levelt; Thomas Yates; Danielle Bodicoat; Kamlesh Khunti; Melanie J Davies; Gerry P McCann
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

10.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.

Authors:  Yan Q Chen; Thomas G Pottanat; Robert W Siegel; Mariam Ehsani; Yue-Wei Qian; Eugene Y Zhen; Ajit Regmi; William C Roell; Haihong Guo; M Jane Luo; Ruth E Gimeno; Ferdinand Van't Hooft; Robert J Konrad
Journal:  J Lipid Res       Date:  2020-06-02       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.